Heterocyclic compounds as protein kinase inhibitors

US9364466B2 · kind B2 · utility

Assignee

• DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

• Ashwani Kumar Verma · New Delhi, IN
• Kumaragurubaran Nagaswamy · Hyderabad, IN
• Lalima Sharma · Chandigarh, IN
• Soma Ghosh · Nakodar, IN
• Balkrishna Ramchandra Kale · Deolali, IN
• Aniruddha Mondal · Falna, IN
• Punit Kumar Srivastava · Manesar, IN
• Sunanda Ghosh Dastidar · New Delhi, IN
• Rijwan Jaffer Momin · Kedgaon, IN
• Pradip Balu Wagh · Nashik, IN
• Sonali Nanasaheb Pansare · Gargoti, IN
• Pramod Raosaheb Markad · Kedgaon, IN
• Yogesh Balasaheb Khairnar · Nashik, IN
• Rie Miyauchi · Funabashi, JP
• Takeshi Murata · Osaka, JP
• Masayuki Ishizaki · Edogawa, JP
• Masatoshi Nagamochi · Koto, JP
• Shin Iimura · Tokyo, JP

Key dates

• Filing date: Feb 13, 2015
• Grant date: Jun 14, 2016
• Expiry date: Feb 13, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.